What is Barclays's price target for BCRX?

Barclays's latest stated price target for BioCryst Pharmaceuticals Inc. (BCRX) is $13, from its action on Apr 18, 2022.

What is Barclays's rating on BCRX?

Barclays rates BCRX Equal Weight, a neutral rating, as of Apr 18, 2022.

When did Barclays last change its view on BCRX?

On Apr 18, 2022, Barclays downgrades to Equal Weight from Overweight, price target $22 to $13.

Barclays BCRX price target and rating history

BioCryst Pharmaceuticals Inc. (BCRX) · Health Care

Barclays rates BioCryst Pharmaceuticals Inc. (BCRX) Equal Weight with a $13 price target, as of its latest action on Apr 18, 2022. It has published 3 rating actions on BCRX since August 2021, including 0 upgrades and 1 downgrade.

Current rating: Equal Weight
Price target: $13
Median target, all firms: Too few
Actions on BCRX: 3

Barclays price target on BCRX

Barclays price target on BCRX, each point a stated target, August 2021 to April 2022.

Every Barclays rating on BCRX

Apr 18, 2022
DowngradeBarclays downgrades to Equal Weight from Overweight, price target $22 to $13
Nov 4, 2021
ReiterateBarclays cuts its price target to $17 from $21, keeps Overweight
Aug 6, 2021
ReiterateBarclays raises its price target to $21 from $20, keeps Overweight

How other firms rate BCRX

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
RBC Capital Markets	Sector Perform	$11	Sep 10, 2026
Evercore ISI	Outperform	$17	Feb 18, 2026

Questions about Barclays and BCRX

What is Barclays's price target for BCRX?: Barclays's latest stated price target for BioCryst Pharmaceuticals Inc. (BCRX) is $13, from its action on Apr 18, 2022.
What is Barclays's rating on BCRX?: Barclays rates BCRX Equal Weight, a neutral rating, as of Apr 18, 2022.
When did Barclays last change its view on BCRX?: On Apr 18, 2022, Barclays downgrades to Equal Weight from Overweight, price target $22 to $13.

More BCRX rating histories

All Barclays ratings BCRX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.